Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma

M. G. Belvisi, D. S. Bundschuh, M. Stoeck, S. Wicks, S. Underwood, C. H. Battram, S. E. Webber, E. B. Haddad, M. L. Foster (Dagenham, United Kingdom; Konstanz, Germany)

Source: Annual Congress 2001 - Inhaled corticosteroids
Session: Inhaled corticosteroids
Session type: Thematic Poster Session
Number: 682
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. G. Belvisi, D. S. Bundschuh, M. Stoeck, S. Wicks, S. Underwood, C. H. Battram, S. E. Webber, E. B. Haddad, M. L. Foster (Dagenham, United Kingdom; Konstanz, Germany). Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma. Eur Respir J 2001; 16: Suppl. 31, 682

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparable efficacy of calcilytic and corticosteroid in short-term and long-term allergic asthma models in vivo
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018



Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 147s
Year: 2001

Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017



High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001



Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Assessment of long-term effects of combined extra-fine beclomethasone and formoterol treatment in asthma patients using functional imaging
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Comparative studies of inhaled corticosteroids in asthma
Source: Eur Respir J 2001; 17: 579-580
Year: 2001


Long-term treatment of aspirin-intolerante asthma with budesonide. Effectivity and safety
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Single inhaler therapy with budesonide/formoterol in an allergic rat model: a new therapeutic strategy in asthma
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017


Clinical efficacy of new non-freon aerosol troventol in asthma patients
Source: Annual Congress 2006 - Recent advances in asthma treatment
Year: 2006

Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids},
Source: Eur Respir J 2012; 40: 570-579
Year: 2012



Clinical evolution of potroom asthma - effects of introducing montelukast to standard treatment with corticosteroid and beta-agonists
Source: Eur Respir J 2001; 18: Suppl. 33, 278s
Year: 2001

Long-term safety data with once-daily budesonide in mild asthma: results from the START study
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003